These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31632814)

  • 1. Pancreatic PCSK9 and its involvement in diabetes.
    Kockx M; Kritharides L
    J Thorac Dis; 2019 Sep; 11(Suppl 15):S2018-S2022. PubMed ID: 31632814
    [No Abstract]   [Full Text] [Related]  

  • 2. PCSK9 inhibitors and diabetes mellitus.
    Vohnout B; Lisičanová J; Havranová A
    Vnitr Lek; 2019; 64(12):1186-1189. PubMed ID: 30704255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 and carbohydrate metabolism: A double-edged sword.
    Filippatos TD; Filippas-Ntekouan S; Pappa E; Panagiotopoulou T; Tsimihodimos V; Elisaf MS
    World J Diabetes; 2017 Jul; 8(7):311-316. PubMed ID: 28751953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
    Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
    Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
    Da Dalt L; Ruscica M; Bonacina F; Balzarotti G; Dhyani A; Di Cairano E; Baragetti A; Arnaboldi L; De Metrio S; Pellegatta F; Grigore L; Botta M; Macchi C; Uboldi P; Perego C; Catapano AL; Norata GD
    Eur Heart J; 2019 Jan; 40(4):357-368. PubMed ID: 29982592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
    Saavedra YGL; Dufour R; Baass A
    J Clin Lipidol; 2015; 9(6):786-793.e1. PubMed ID: 26687699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
    Langhi C; Le May C; Gmyr V; Vandewalle B; Kerr-Conte J; Krempf M; Pattou F; Costet P; Cariou B
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1288-93. PubMed ID: 19878649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
    Bonnefond A; Yengo L; Le May C; Fumeron F; Marre M; Balkau B; Charpentier G; Franc S; Froguel P; Cariou B;
    Diabetologia; 2015 Sep; 58(9):2051-5. PubMed ID: 26049403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.
    Ibarretxe D; Girona J; Plana N; Cabré A; Ferré R; Amigó N; Guaita S; Mallol R; Heras M; Masana L
    Clin Investig Arterioscler; 2016; 28(2):71-8. PubMed ID: 26743379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus.
    Wang M; Li YF; Guo YG; Chen MM; Jiang ZL; Song JY
    J Geriatr Cardiol; 2016 May; 13(4):312-5. PubMed ID: 27403140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 signaling pathways and their potential importance in clinical practice.
    Wiciński M; Żak J; Malinowski B; Popek G; Grześk G
    EPMA J; 2017 Dec; 8(4):391-402. PubMed ID: 29209441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
    Tóth Š; Fedačko J; Pekárová T; Hertelyová Z; Katz M; Mughees A; Kuzma J; Štefanič P; Kopolovets I; Pella D
    Cardiol Ther; 2017 Dec; 6(2):281-289. PubMed ID: 28623549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
    Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V
    Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients.
    Eisenga MF; Zelle DM; Sloan JH; Gaillard CAJM; Bakker SJL; Dullaart RPF
    Diabetes Care; 2017 Jul; 40(7):894-901. PubMed ID: 28461454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.